Brandt Benny, Levin Gabriel, Leitao Mario M
Department of Gynecologic Oncology, Sheba Medical Center, Ramat Gan, Israel.
Department of Gynecologic Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Curr Treat Options Oncol. 2022 Jan;23(1):1-14. doi: 10.1007/s11864-021-00919-z. Epub 2022 Feb 15.
Radical hysterectomy with pelvic lymph node assessment is the standard initial therapy for early-stage cervical cancer. Radical hysterectomy via laparotomy (an "open" approach) was first described more than 100 years ago and has been the standard for decades. Minimally invasive surgery (MIS) has been increasingly adopted by many surgeons due to its reported perioperative benefits. MIS was deemed safe for radical hysterectomy for many years based on multiple retrospective publications. Recently, the Laparoscopic Approach to Cervical Cancer (LACC) trial reported that patients randomized to MIS had inferior oncologic outcomes. The results of the LACC trial and subsequent retrospective studies led multiple professional societies to state that open radical hysterectomy should remain the gold standard surgical approach. We acknowledge that the open approach for radical hysterectomy is an appropriate option for all cervical cancer patients eligible for surgical treatment. However, considering the limitations of the LACC trial and the available data from other retrospective studies, we feel the MIS approach should not be simply abandoned. There may still be a role for MIS in cervical cancer surgery for properly and carefully selected cases and with detailed counseling; surgeons should analyze their own outcomes closely in order to perform such counseling. Modification of surgical technique and maintaining proper oncologic surgical principles are key for MIS to remain a viable option. Tumor manipulation and contamination should be avoided. Transcervical uterine manipulators should not be used. Cervical and tumor containment prior to colpotomy, as is performed during an open approach, is required. This will all require validation in future trials. We await the results of ongoing randomized trials to further inform us. A one-size-fits-all approach may be short-sighted; we may need to decide treatment strategy based on the notion of the right surgical approach for the right patient by the right surgeon.
根治性子宫切除术加盆腔淋巴结评估是早期宫颈癌的标准初始治疗方法。经腹根治性子宫切除术(一种“开放”手术方式)早在100多年前就有描述,并且几十年来一直是标准术式。由于微创外科手术(MIS)在围手术期具有诸多益处,越来越多的外科医生开始采用该术式。基于多项回顾性研究报告,多年来MIS一直被认为可安全用于根治性子宫切除术。最近,腹腔镜治疗宫颈癌(LACC)试验报告称,随机接受MIS治疗的患者肿瘤学结局较差。LACC试验结果及随后的回顾性研究导致多个专业学会指出,开放性根治性子宫切除术应仍是金标准手术方式。我们承认,对于所有适合手术治疗的宫颈癌患者,开放性根治性子宫切除术是一种合适的选择。然而,考虑到LACC试验的局限性以及其他回顾性研究的现有数据,我们认为不应简单地摒弃MIS术式。对于经过适当且仔细挑选的病例,并给予详细的咨询指导,MIS在宫颈癌手术中可能仍有一席之地;外科医生应密切分析自身手术结果,以便进行此类咨询指导。手术技术的改进以及遵循正确的肿瘤外科手术原则是MIS继续成为可行选择的关键。应避免肿瘤操作和污染。不应使用经宫颈子宫操纵器。与开放性手术一样,在阴道切开术前需要对宫颈和肿瘤进行封闭。所有这些都需要在未来的试验中得到验证。我们期待正在进行的随机试验结果,以进一步为我们提供信息。一刀切的方法可能是短视的;我们可能需要根据合适的外科医生为合适的患者选择合适的手术方式这一理念来决定治疗策略。